ABCB1 and cancer: As an alternative, we and others have been investigating the potential repurposing of tyrosine kinase inhibitors (TKIs) as modulators of ABCB1 and ABCG2 to resensitize multidrug-resistant cancer cells to chemotherapeutic agents [18,19,20,21,22,23,24].